These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 17460396)
1. Rituximab (anti-CD20 monoclonal antibody)--ultimate or first choice in pemphigus? Hertl M; Eming R; Borradori L Dermatology; 2007; 214(4):275-7. PubMed ID: 17460396 [No Abstract] [Full Text] [Related]
2. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. El Tal AK; Posner MR; Spigelman Z; Ahmed AR J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351 [TBL] [Abstract][Full Text] [Related]
3. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402 [TBL] [Abstract][Full Text] [Related]
4. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Kong HH; Prose NS; Ware RE; Hall RP Pediatr Dermatol; 2005; 22(5):461-4. PubMed ID: 16191003 [TBL] [Abstract][Full Text] [Related]
5. Rituximab in refractory pemphigus vulgaris. Sorce M; Aricò M; Bongiorno MR Dermatol Ther; 2008 Jul; 21 Suppl 1():S6-9. PubMed ID: 18727815 [TBL] [Abstract][Full Text] [Related]
6. Anti-B- cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus--an update. Arin MJ; Hunzelmann N Eur J Dermatol; 2005; 15(4):224-30. PubMed ID: 16048747 [TBL] [Abstract][Full Text] [Related]
8. Rituximab for pemphigus vulgaris. Joly P; D'Incan M; Musette P N Engl J Med; 2007 Feb; 356(5):521; author reply 521-2. PubMed ID: 17267915 [No Abstract] [Full Text] [Related]
9. Rituximab in severe pemphigus. Schmidt E; Goebeler M; Zillikens D Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216 [TBL] [Abstract][Full Text] [Related]
10. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Goh MS; McCormack C; Dinh HV; Welsh B; Foley P; Prince HM Br J Dermatol; 2007 May; 156(5):990-6. PubMed ID: 17355229 [TBL] [Abstract][Full Text] [Related]
11. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662 [TBL] [Abstract][Full Text] [Related]
12. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). Morrison LH J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367 [TBL] [Abstract][Full Text] [Related]
13. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment. Connelly EA; Aber C; Kleiner G; Nousari C; Charles C; Schachner LA Pediatr Dermatol; 2007; 24(2):172-6. PubMed ID: 17461818 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of rituximab in patients with severe pemphigus. Schmidt E; Hennig K; Mengede C; Zillikens D; Kromminga A Clin Immunol; 2009 Sep; 132(3):334-41. PubMed ID: 19502112 [TBL] [Abstract][Full Text] [Related]
15. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment. Prodanovic EM; Korman NJ J Dermatolog Treat; 2008; 19(6):1-3. PubMed ID: 18720187 [TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports. Allen KJ; Wolverton SE J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]